PROTAC 工程化蛋白/DNA 纳米抗原是癌症免疫治疗中树突状细胞疫苗的有效增强剂
PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
撤稿说明：树突状细胞疫苗与负载白细胞介素-15 和抗β-catenin siRNA 的纳米颗粒联合肿瘤免疫治疗可显著抑制肿瘤生长并诱导抗肿瘤免疫反应
英文原题：Retraction Note: Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response.
查看英文原题
Retraction Note: Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
摘要
这条来源本身就没有摘要（PubMed 未提供），不是「还没翻译」。可以点最下面的「在 PubMed 查看」打开原文献页面。
论文信息
- 作者
- Salehi AM、Kheshti、Hajizadeh F、Barshidi A、Rashidi B、Ebrahimi F、Bahmanpour S、Karpisheh V
- 第一作者单位
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.Iran
- 通讯作者单位
- Hematology, Immune Cell Therapy, and Stem Cell Transplantation Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran. majidiz.n@umsu.ac.ir.Iran
- 文献类型
- 撤稿声明
- 期刊
- Pharmaceutical research2023 Feb
- 原文标识
- PubMed 36477758 · DOI 10.1007/s11095-022-03456-y